Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2026-03-19 00:00:00 ET · period of report 2026-03-17 · accession 0001610717-26-000122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | 2026-03-17 | CTMX | Ogden Christopher | CFO | S - Sale | $6.42 | -19.3K | 296.9K | -6% | -$124.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | S | D | 19,323 | $6.42 | 296,948 | D | — | — | (F2) Includes 173,082 RSUs. |